AKT1 and esophageal squamous cell carcinoma: Our data indicate that under chemotherapy, ESCC cells utilize the activation of AKT signaling for adaptation and survival, while further administration of RAC1 inhibitor can reverse both the activation of AKT signaling and chemoresistance.